LixiLan-L Study

Read about the efficacy and safety of Suliqua in this clinical summary of the phase III LixiLan-L study. This study demonstrates the efficacy of Suliqua a titratable fixed-ratio combination of insulin glargine + lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin.
_{Aroda VR, et al. Diabetes Care. 2016; 39: 1972–80}